W2O, the No. 1 ranked independent healthcare PR firm, has acquired Elysia Group, an economic and outcomes research outfit based in New York.

Elysia, which has offices in Taipei and Shanghai, provides modeling approaches to help pharmaceutical and medical device companies gauge cost-effectiveness, market sizing, forecasting and portfolio analysis.

Bruce Wang, Elysia CEO/co-founder, and Wesley Furnback, president/co-founder, join W2O as health economics and real-world evidence-practice leaders.

They report to Rita Glaze, W2O's commercial strategy and market access practice leader.

Elysia will work closely with W2O’s Discern Health unit, which counsels clients on performance measures and innovative payment models that shape the market for their products and services.

“The collective expertise and capabilities of Elysia and Discern enable us to help clients plan for and execute their commercial and market access strategies at greater quality and depth than ever before,” said Glaze.

The Elysia deal is W20’s seventh acquisition since it announced a partnership in 2019 with New Mountain Capital.

W2O registered $218.9M in healthcare fees in 2019, according to O'Dwyer's ranking of PR firms.